Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Table 5 Baseline hematological prognostic indicators markers for patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1immunotherapy, mean ± SD
Characteristics
Stats
Normal range
Height (cm)168.3 ± 8.0140-190
Weight (kg)67.7 ± 12.040-100
ALLC (109/L)6.0 ± 1.93.5-9.5
RDW (%)15.2 ± 3.811.6-14.8
PLT (109/L)178.2 ± 63.7125-350
ANC (109/L)4.1 ± 1.41.8-6.3
ALC (109/L)1.4 ± 0.51.1-3.2
AMC (109/L)0.4 ± 0.10.1-0.6
AEC (109/L)0.2 ± 0.20.02-0.52
ALB (g/L)41.4 ± 4.040-55
LDH (IU/L)240.0 ± 154.9109-245
FIB (g/L)3.6 ± 0.72-4
Dimer (ng/ml)257.3 ± 647.30-500
CEA (ng/mL), n (%)6 (24.0%)0-5
19 (76.0%)-
CA199 (IU/mL), n (%)13 (52.0%)0-37
12 (48.0%)-